{"id":"NCT02484911","sponsor":"First Affiliated Hospital of Harbin Medical University","briefTitle":"Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting","officialTitle":"Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting---A Randomized Single Center Phase III Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05","primaryCompletion":"2016-09","completion":"2017-01","firstPosted":"2015-06-30","resultsPosted":"2017-03-30","lastUpdate":"2017-03-30"},"enrollment":120,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Chemotherapy-induced Nausea and Vomiting"],"interventions":[{"type":"DRUG","name":"Olanzapine","otherNames":[]},{"type":"DRUG","name":"Aprepitant","otherNames":[]},{"type":"DRUG","name":"Palonosetron","otherNames":[]},{"type":"DRUG","name":"Dexamethasone","otherNames":[]}],"arms":[{"label":"Olanzapine regimen","type":"EXPERIMENTAL"},{"label":"Control regimen","type":"OTHER"}],"summary":"The purpose of the study is to mainly evaluate the efficacy and safety of aprepitant in combination with olanzapine ,palonosetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly or moderately emetogenic chemotherapy.","primaryOutcome":{"measure":"Proportion of Participants Receiving HEC With Complete Response in Overall Phase","timeFrame":"0 to 120 hours","effectByArm":[{"arm":"Olanzapine Regimen","deltaMin":20,"sd":null},{"arm":"Control Regimen","deltaMin":15,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.397"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":["9629870","8181539","10728886","12736106","8232489","23598819","11030465","22141732","19775450","22024310"],"seeAlso":["http://www.ncbi.nlm.nih.gov/pubmed/?term=Differential+involvement+of+neurotransmitters+through+the+time+course+of+cisplatin-induced+emesis+as+revealed+by+therapy+with+specific+receptor+antagonists","http://www.ncbi.nlm.nih.gov/pubmed/8232489","http://www.ncbi.nlm.nih.gov/pubmed/?term=Effects+of+iron+and+deferoxamine+on+cisplatin-induced+emesis%3A+further+evidence+for+the+role+of+free+radicals","http://www.ncbi.nlm.nih.gov/pubmed/23598819","http://www.ncbi.nlm.nih.gov/pubmed/?term=Diemunsch+P%2C+Grelot+L.+et+al.+Potential+of+substance+P+antagonists+as+antiemetics","http://www.ncbi.nlm.nih.gov/pubmed/?term=The+novel+NK1+receptor+antagonist+MK-0869+(L-754%2C030)+and+its+water+soluble+phosphoryl+prodrug%2C+L-758%2C298%2C+inhibit+acute+and+delayed+cisplatin-induced+emesis+in+ferrets.+Neuropharmacology.","http://www.ncbi.nlm.nih.gov/pubmed/22141732","http://www.ncbi.nlm.nih.gov/pubmed/19775450","http://www.ncbi.nlm.nih.gov/pubmed/22024310"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":56},"commonTop":["Drowsiness","Abdominal distension","Headache","Abdominal distension","Dizzy"]}}